Australia must make biotechnology a strategic national industry and build on its clinical trial strengths as political pressure on U.S. scientific institutions and China’s rise reshape global drug ...
Guangzhou Patronus Biotech Co. Ltd. has obtained ethical approval in Australia from Bellberry Ltd. for a first-in-human phase I trial of three novel multi-stage virus-like-particle (VLP)-based ...
Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Zai Lab. Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing ...
Gilead Sciences Inc. is paying $1.28 billion in cash to acquire Pepstar Therapeutics Ltd.’s oral IL-23 receptor inhibitor program, including lead asset HCXT-2001, to deepen its presence in immunology ...
Xencor Inc. plans to talk with the U.S. FDA next year about the possibility of accelerated approval for XmAb-819, an ENPP3xCD3 T-cell engaging bispecific antibody, in patients with advanced clear cell ...
The bald figures show U.K. biotech continues to attract funding, but two new reports highlight the ongoing structural weakness of dependence on overseas investors and a lack of the domestic capital ...
Cambridge, Mass.-based Alkeus Pharmaceuticals Inc.’s dosing this summer of the first patient in its phase III Northstar study ...
The 2026 European Society of Medical Oncology (ESMO) 2026 annual meeting kicked off with a bit of drama, as Merck & Co. Inc.
Researchers from Recludix Pharma Inc. presented preclinical data on first-in-class inhibitors of the Bruton tyrosine kinase (BTK) SH2 domain, a novel approach for the treatment of multiple sclerosis ...
Researchers from Oregon Health & Science University investigated the potential of SU-056, a small-molecule Y-box binding protein 1 (YB-1) inhibitor, to directly suppress osteosarcoma and improve ...
Effector memory T cells (TEMs) play a crucial role in the pathogenesis of autoimmune diseases such as inflammatory bowel disease (IBD), and they highly express the voltage-gated potassium channel Kv1.
Ascletis Pharma Inc. has submitted an IND application to the FDA for ASC-39 oral tablets, an oral small-molecule selective amylin receptor agonist, for the treatment of obesity. A phase I trial is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results